|1.||Fukushima, Masakazu: 25 articles (01/2015 - 01/2002)|
|2.||Peters, G J: 17 articles (11/2011 - 03/2000)|
|3.||Danenberg, Peter V: 15 articles (05/2014 - 03/2002)|
|4.||Lenz, Heinz-Josef: 13 articles (05/2014 - 01/2002)|
|5.||Danenberg, Kathleen D: 13 articles (01/2014 - 03/2002)|
|6.||Peters, Godefridus J: 12 articles (06/2014 - 01/2002)|
|7.||Fukushima, M: 12 articles (08/2011 - 01/2000)|
|8.||Scagliotti, Giorgio V: 10 articles (09/2015 - 02/2006)|
|9.||Kawakami, Kazuyuki: 10 articles (11/2006 - 09/2002)|
|10.||Marverti, Gaetano: 9 articles (11/2015 - 08/2009)|
|1.||Colorectal Neoplasms (Colorectal Cancer)
11/01/2000 - "We assessed the importance of Thymidylate Synthase (TS) expression as a prognostic factor and as an index of therapeutic efficacy in patients with colorectal carcinoma. "
09/01/2014 - "The effects of thymidylate synthase (TS) polymorphisms on susceptibility to colorectal cancer (CRC) have been investigated in many studies, but the results remain conflicting rather than conclusive. "
07/01/2012 - "Although many studies have investigated the prognostic effect of thymidylate synthase (TS) in colorectal cancer, no consensus has been reached. "
01/01/2012 - "Studies investigating the association of 2R/3R polymorphism in the thymidylate synthase 5'-untranslated enhanced region (TSER) and colorectal cancer (CRC) risk have reported conflicting results. "
12/01/2006 - "Despite previous studies, uncertainty has persisted about the role of thymidylate synthase (TS) and p53 status as markers of prognosis in colorectal cancer (CRC). "
08/01/2001 - "Chemotherapeutic agents targeting thymidylate synthase (TS) are effective against human tumors. "
05/27/2000 - "In advanced colorecal cancer, clinical results have confirmed the therapeutic efficacy of direct and indirect thymidylate synthetase inhibitors. "
11/01/2012 - "The expressions of CD133 and thymidylate synthetase of metastatic tumors were also evaluated in our studies. "
07/01/2012 - "Several studies have evaluated the association between polymorphisms of thymidylate synthase (TS) and cancer risk in diverse populations but with conflicting results. "
02/01/2004 - "Many experimental studies have revealed that enhanced thymidylate synthase (TS) expression is significantly correlated with higher proliferative activity of tumor cells, which may account for a poor prognosis of high-TS patients. "
|3.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/01/2015 - "It remains controversial whether thymidylate synthase (TS) protein expression is associated with survival for patients with non-small cell lung cancer (NSCLC). "
01/01/2015 - "Prognostic and predictive significance of thymidylate synthase protein expression in non-small cell lung cancer: a systematic review and meta-analysis."
06/01/2014 - "Thymidylate synthase (TYMS) is an important chemotherapeutic target in non-small cell lung cancer (NSCLC). "
01/01/2014 - "Prognostic significance of thymidylate synthase in postoperative non-small cell lung cancer patients."
09/01/2012 - "Assessment of thymidylate synthase expression in biopsy specimens and corresponding resection specimens of non-small-cell lung cancer."
|4.||Stomach Neoplasms (Stomach Cancer)
02/01/2014 - "In our study, we investigate the possible association of thymidylate synthase polymorphism, 28 bp tandem repeat in 5'-UTR (transcription enhancer element) with susceptibility of colorectal and gastric cancer in Tunisian population. "
01/01/2012 - "Our meta-analysis suggests that the 3R variant of Thymidylate synthase 5'-untranslated enhanced region 2R/3R polymorphism contributes to gastric cancer risk in the Caucasian population, while any association in Asian populations needs further study."
01/01/2012 - "Studies investigating the association between 2R/3R polymorphisms in the thymidylate synthase 5'-untranslated enhanced region (TYMS 5'-UTR) and gastric cancer risk have generated conflicting results. "
02/01/2014 - "In addition, we found a positive association between SL (2R/3R) genotype in the thymidylate synthase 5'-UTR and gastric cancer risk (P = 0.015; OR 4.46; 95 % CI 1.08-19.64). "
04/01/2013 - "Immunohistochemical staining was employed to examine expression of stem cell marker CD44 and drug-resistance protein thymidylate synthase (TS) in 71 cases with gastric cancer. "
|5.||Neoplasm Metastasis (Metastasis)
03/01/2014 - "The prognostic value of p53, Ki-67 and thymidylate synthase in patients undergoing radical resection of colorectal liver metastases."
04/01/2007 - "Thymidylate synthase expression in primary colorectal tumours is correlated with its expression in metastases."
08/20/2005 - "Thymidylate synthase in nodal metastases: prognostic for chemosensitivity but not for adjuvant therapy?"
11/01/2002 - "There was no correlation between p53, DCC or thymidylate synthase immunohistochemical staining, or between p53 PCR-SSCP analysis, and survival for either hepatic metastases or the colorectal primary tumour. "
11/01/2002 - "Sixty-three patients with hepatic metastases and 40 corresponding colorectal primary tumours were studied using immunohistochemical staining for p53, DCC and thymidylate synthase, as well as p53 gene mutations using polymerase chain reaction-single-stranded conformational polymorphism (PCR-SSCP) analysis. "
|2.||Dihydrouracil Dehydrogenase (NADP) (Dihydropyrimidine Dehydrogenase)
|4.||raltitrexed (D 1694)
|8.||Leucovorin (Folinic Acid)
|9.||Messenger RNA (mRNA)
|1.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)